2023-11-08 07:00:00
New Research Finds Clozapine Blood Monitoring Requirements May Be Unnecessarily Strict
A new study conducted by the Dutch ClozapinePlus Working Group has found that the current strict blood monitoring requirements for clozapine, the only antipsychotic effective for treatment-resistant schizophrenia, may be unnecessary. The researchers, led by psychiatrist Peter Schulte, discovered that the risk of agranulocytosis, a potentially life-threatening condition, is highest in the first 18 weeks of treatment with clozapine. However, they also found that overall, there is no greater risk of neutropenia with clozapine use than with other antipsychotics.
The current guidelines in the Netherlands mandate regular monitoring of white blood cell counts for the entire duration of clozapine treatment due to the risk of agranulocytosis. However, the ClozapinePlus Working Group’s literature review found that frequent blood checks do not demonstrably reduce the risk of agranulocytosis. In fact, patients could potentially be at risk of having to stop taking clozapine unnecessarily based on abnormal blood values.
As a result of their findings, the Dutch researchers recommend determining granulocyte counts only during the first 18 weeks of clozapine use. They suggest that the frequency of blood checks should be decided in consultation with the prescriber and the patient. Additionally, they argue that clozapine only needs to be discontinued when a granulocyte count is below a certain threshold, and the drug may be restarted if the benefits outweigh the risks.
Peter Schulte, the lead researcher, anticipates that these findings will lead to clozapine being prescribed more often for treatment-resistant schizophrenia, ultimately reducing mortality among this group of users. He believes that by reducing the number of suicides, this change in the monitoring requirements could have a significant impact on the management of treatment-resistant schizophrenia.
The study’s results were published in Schizophrenia Research and are expected to have a major impact on the current guidelines for clozapine use. As further research is conducted, these findings may also have implications for the use of clozapine in other countries around the world.]
#Stop #blood #checks #weeks #clozapine